macular edeam secondary to retinal vein occlusion
Conditions
Interventions
the ranibizumab group : The ranibizumab group, The patients received ranibizumab intravitreal injections in the first three months as the initial treatment. Patients might receive repeat injections d
The recurrence of macular edema is defined as the central macular thickness = 300 um, or the increase of central macular thickness = 50 um from the baseline.
the combination group:The combination group (ranibizumab combined with dexamethasone intravitreal implant).
In the combination group, patients received an intravitreal injection of dexamethasone impla
Sponsors
Sanmenxia Eye Hospital
Eligibility
Sex/Gender
All
Age
42 Years to 79 Years
Inclusion criteria
Inclusion criteria: Patients over 18 years of age with retinal vein occlusion and macular edema confirmed by OCT and FFA, Patients with optimal corrected visual acuity between 1.30-0.30(LogMAR visual acuity) ; OCT shows CMT=290um, patients with new onset within 3 months who had not received anti-VEGF drugs or laser therapy before onset; Patients with good compliance and no obvious surgical contraindications by auxiliary examination.
Exclusion criteria
Exclusion criteria: Patients with other retina-related diseases, such as diabetic retinopathy, age-related macular degeneration, retinal vasculitis, etc. Previous history of glaucoma, ocular trauma and high myopia; Patients with severe cataract or vitreous hematocele and other refractive interstitial opacity affecting fundus imaging; History of stroke or myocardial infarction, or severe unstable systemic disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median LogMAR Visual Acuity;Central macular thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of recurrence of ME(times);Mean time(days);number of injections (times); | — |
Countries
China
Contacts
Public ContactXiaohui Cai
Sanmenxia Eye Hospital
Outcome results
None listed